Key facts
- Thrombolex’s last known valuation is $96.0M (Mar 2026).
- It has raised $75.6M across 1 recorded rounds; the latest was Later Stage VC ($50.0M) in Mar 2026.
- Notable investors include OrbiMed, Delaware Crossing Investor Group, Lung, National Heart, and Blood Institute.
- Thrombolex has filed 3 Form Ds with the SEC since 2017, most recently Feb 2020 ($9.8M sold to 33 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Thrombolex
Funding rounds
1 roundsAbout Thrombolex
Developer of endovascular catheters intended for interventional procedures, particularly for pharmaco-mechanical catheter-directed thrombolysis. The company's device is used particularly in catheter-directed thrombolysis and rapidly creates multiple channels so the endogenous lytic can flow into the culprit thrombus, enhanced by infused exogenous thrombolytics, enabling hospitals to improve the treatment outcomes for patients suffering from arterial and venous thromboembolic conditions.
- Sector
- Healthcare
- HQ
- New Britain, PA, United States
- Founded
- 2016
- Employees
- 17
- Website
- thrombolex.com/
- Ownership
- Privately Held (backing)
Thrombolex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thrombolex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thrombolex in its N-PORT filings yet. We sweep new filings monthly.